Evans syndrome is a rare autoimmune condition in which the immune system attacks its own blood cells. Specifically, the body produces antibodies that destroy red blood cells, platelets, and sometimes white blood cells, either at the same time or one after the other. What makes Evans syndrome distinct from other blood disorders is this combination: it involves at least two types of blood cell destruction happening together, most commonly autoimmune hemolytic anemia (the breakdown of red blood cells) and immune thrombocytopenia (the destruction of platelets).
How the Immune System Turns on Itself
In a healthy immune system, B cells produce antibodies that target foreign invaders like bacteria and viruses. In Evans syndrome, B cells malfunction and create antibodies that latch onto the surface of the body’s own blood cells, marking them for destruction. The antibodies that attack red blood cells are a “warm” type, meaning they bind to red blood cells at normal body temperature. A separate set of antibodies targets proteins on the surface of platelets.
Recent research has shed light on the role T cells play in driving this process. When a specific type of immune cell (CD8+ T cells) becomes overactivated, it releases a signaling molecule called interferon gamma, which in turn stimulates the rogue B cells to ramp up their attack on red blood cells and platelets. A deficiency in a protein that normally keeps inflammatory responses in check may allow this cycle to spiral, disrupting the immune system’s ability to regulate itself.
Primary vs. Secondary Evans Syndrome
Evans syndrome is classified as either primary or secondary. Primary Evans syndrome occurs on its own, with no identifiable underlying cause. Secondary Evans syndrome develops alongside or as a result of another condition. Common associations include lupus, chronic lymphocytic leukemia, and primary immunodeficiencies.
In a large study of pediatric patients, about 25% of children initially diagnosed with Evans syndrome were eventually found to have an underlying condition, most often lupus or a primary immunodeficiency that wasn’t apparent when symptoms first appeared. Genetic analyses have found immune-related gene variants in up to 65% of a subset of pediatric patients, suggesting that many cases have a deeper genetic root. Children who develop lupus-related Evans syndrome tend to be older at onset (median age 13 vs. 5 years) and are overwhelmingly female.
Symptoms to Recognize
Because Evans syndrome attacks different types of blood cells, it produces two overlapping sets of symptoms. The anemia side, caused by the destruction of red blood cells, leads to fatigue, weakness, pale or yellowish skin (jaundice), dark urine, and shortness of breath. These symptoms reflect the fact that your body can’t deliver oxygen efficiently when red blood cells are being broken down faster than they can be replaced.
The low-platelet side causes bleeding-related symptoms. You might notice tiny red or purple dots on the skin called petechiae, larger areas of bruising (purpura), bleeding gums, nosebleeds, or unusually heavy menstrual periods. In some people, white blood cells are also affected, which increases vulnerability to infections. Symptoms can appear suddenly and severely, or develop gradually. One of the hallmarks of Evans syndrome is that the two types of blood cell destruction don’t always happen simultaneously. You might first develop low platelets, then months or even years later develop anemia, or vice versa.
How It’s Diagnosed
Diagnosing Evans syndrome requires confirming that at least two blood cell lines are being destroyed by the immune system. A standard blood count will show low red blood cells, low platelets, or both. The key confirmatory test is the direct antiglobulin test (also called a Coombs test), which detects the antibodies stuck to the surface of red blood cells. A positive result, combined with low platelets and evidence that the bone marrow is actually trying to produce enough cells, points toward Evans syndrome.
Because Evans syndrome can be secondary to other conditions, doctors typically run additional tests to rule out lupus, lymphoma, and immunodeficiency disorders. This is especially important because the underlying condition, if present, often shapes the treatment approach.
Treatment: First and Later Lines
First-line treatment relies on corticosteroids and intravenous immunoglobulin (IVIG). Corticosteroids work by broadly suppressing the overactive immune response, while IVIG floods the system with normal antibodies that can temporarily block the destruction of blood cells. Many patients respond initially, but Evans syndrome is known for relapsing.
When the disease comes back or doesn’t respond to initial treatment, a medication called rituximab is commonly used. It works by targeting and depleting the B cells responsible for producing the harmful antibodies. The first consensus guidelines for managing Evans syndrome in adults, published recently, now recommend a drug called fostamatinib as a third-line option, or even second-line for patients who have experienced blood clots. Traditional immunosuppressive drugs have been moved further down the treatment ladder in these updated recommendations.
Surgical removal of the spleen (splenectomy) remains an option for refractory cases, since the spleen is a major site where antibody-coated blood cells are filtered out and destroyed. Studies show splenectomy produces an initial response in about 86% of Evans syndrome patients, but roughly 43% relapse within the first year, requiring further treatment. This relapse rate is notably higher than what’s seen when splenectomy is performed for immune thrombocytopenia alone.
Course of the Disease Over Time
Evans syndrome tends to follow a relapsing and remitting pattern. People can have long stretches of stable blood counts, then experience flares that require treatment escalation. A large study tracking children with Evans syndrome into adulthood found that by 10 years after diagnosis, about 55% had achieved sustained remission of their low platelet counts, and 78% had their anemia under lasting control. But the need for more aggressive treatments increased with age: by age 20, 88% of patients had required at least one second-line therapy, compared to 47% by age 10.
The frequency of other immune-related problems also climbed over time. By age 20, 74% of patients in this cohort had developed at least one additional autoimmune or immune-related complication beyond the blood cell destruction itself. This pattern highlights that Evans syndrome is not just a blood disorder but often reflects broader immune dysregulation that can evolve over a person’s lifetime.
Long-Term Outlook
Survival at 15 years after diagnosis was 84% in the largest long-term pediatric study available. The deaths that did occur were associated with complications from treatment, severe infections, or undiagnosed underlying immunodeficiencies rather than the blood cell destruction itself. Patients who had required the most aggressive treatments, including splenectomy and multiple second-line therapies, faced higher risks. The transition from adolescence to adulthood appears to be a particularly high-risk period, as the disease often shifts from active blood cell destruction toward broader immune complications that require ongoing management.
Adults who develop Evans syndrome for the first time in middle age or later tend to have a different clinical profile from those whose disease began in childhood. Pediatric-onset patients who carry the condition into adulthood form a distinct group with a heavier treatment burden and more complex immune profiles than adults diagnosed later in life.